Syndax Pharmaceuticals (SNDX) Gains from Investment Securities (2015 - 2025)

Syndax Pharmaceuticals' Gains from Investment Securities history runs 11 years deep, the most recent figure standing at $4.0 million for Q4 2025.

• In Q4 2025, Gains from Investment Securities fell 65.98% year-over-year to $4.0 million; the TTM figure through Dec 2025 stood at $4.0 million (down 65.98% YoY), while the FY2025 annual figure was $4.0 million, down 65.98% from the prior year.
• Gains from Investment Securities was $4.0 million for Q4 2025 at Syndax Pharmaceuticals, down from $11.7 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $17.0 million in Q4 2022 to a low of $7778.0 in Q2 2022.
• Historically, Gains from Investment Securities has averaged $4.0 million across 5 years, with a median of $2.3 million in 2021.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities tumbled 99.69% in 2022, then soared 3866.96% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at $10.1 million in 2021, then surged by 68.33% to $17.0 million in 2022, then plunged by 93.53% to $1.1 million in 2023, then soared by 962.55% to $11.7 million in 2024, then tumbled by 65.98% to $4.0 million in 2025.
• The last three Gains from Investment Securities figures came in at $4.0 million (Q4 2025), $11.7 million (Q4 2024), and $1.1 million (Q4 2023), per Business Quant data.